Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Explore this paper's citation graph
Summary
Large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
- Type
- article
- Published
- 2013-11-13
- Cited by
- 1,496
- References
- 34
- Access
- Open access
- OpenAlex
- https://openalex.org/W2026134786
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2359152
Keywords
Myelodysplastic syndromes, Gene, Oncology, Internal medicine, Univariate analysis
References
- International scoring system for evaluating prognosis in myelodysplastic syndromes.
- ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- Advances in understanding cancer genomes through second-generation sequencing
- Clinical and biological implications of driver mutations in myelodysplastic syndromes.
- Classification and prognostic evaluation of myelodysplastic syndromes.
- The origin and evolution of mutations in Acute Myeloid Leukemia
- A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders
- L1 Penalized Estimation in the Cox Proportional Hazards Model
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
- Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- Frequent pathway mutations of splicing machinery in myelodysplasia
- Unraveling the molecular pathophysiology of myelodysplastic syndromes.
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
- RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES
- Mutation in TET2 in myeloid cancers.
- Controlling the false discovery rate: a practical and powerful approach to multiple testing
- Sequencing technologies — the next generation
- Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Cited by
- Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder (复方青黄散) in Patients with Myelodysplastic Syndromes
- Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
- Clonal hematopoiesis of indeterminate potential associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
- The Role of U2AF1 Mutations in the Pathogenesis of Myelodysplastic Syndromes
- Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
- The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.
- Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation
- Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
- Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?
- Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
- Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process
- Understanding Ten-Eleven Translocation-2 in Hematological and Nervous Systems
- SRSF2 Mutations Contribute to Myelodysplasia Through Mutant-Specific Effects on Exon Recognition
- Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
- The utility of next‐generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
- High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
- Applying a Weight-of-Evidence Approach to Evaluate Relevance of Molecular Landscapes in the Exposure-Disease Paradigm
- Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
- Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
- Splicing factor mutations and cancer
Related papers
- Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)
- 237 CLINICIAN UTILIZATION OF THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) FOR NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS
- Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
- [Molecular international prognostic scoring system for myelodysplastic syndromes].
- High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes
- P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM
- 99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
- Prognostic models in myelodysplastic syndromes.
- Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
- Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS‐M) prediction in myelodysplastic syndromes